As previously disclosed, the studies did not meet pre-specified co-primary, secondary, or exploratory biomarker endpoints The ...

Charting, Price Performance, News & Related Contracts.

Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...

CHICAGO, Jan. 15, 2026 /PRNewswire/ -- The Alzheimer's Association Dementia Care Navigation Roundtable (DCNR) today released a new white paper offering guidance to help health care organizations build ...

The Alzheimer’s Association will host Picklers Go Purple, a pickleball fundraiser from noon to 4 p.m. Jan. 24 at Picklers ...

Alzheimer’s is not normal aging. It’s a brain disease that causes problems with memory, thinking, and behavior. Corning ...

In addition, hypothetical trading does not involve financial risk, and no hypothetical trading record can completely account for the impact of financial risk in actual trading. For example, the ...

Transverse colon samples from confirmed Alzheimer’s disease cases showed distinct gut microbiome and proteomic shifts, ...

Armed with preliminary clinical data, US start-up Alzheon has raised $10 million to help take its oral Alzheimer's therapy ALZ-801 into a phase II/III trial. The financing means that Alzheon can now ...

The saga of Cassava Sciences' development of Alzheimer's disease therapy simufilam has come to its dismal end. The company has reported top-line data from a second phase 3 trial of the drug, which ...

New designation strengthens national leadership and accelerates adoption of brain health, early detection and high-quality dementia care practices ---- CHICAGO, Jan. 6, 2026 /PRNewswire/ -- The ...

The U.S. Food and Drug Administration (FDA) will meet Cognition during a Type C meeting scheduled for the second half of January 2026. During the meeting, the next clinical studies for zervimesine in ...